How to buy Atea Pharmaceuticals (AVIR.US) stock |

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atea Pharmaceuticals stock

Own Atea Pharmaceuticals stock in just a few minutes.

Atea Pharmaceuticals, Inc is a biotechnology business based in the US. Atea Pharmaceuticals shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals employs 39 staff and has a trailing 12-month revenue of around USD$48.6 million.

How to buy shares in Atea Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Atea Pharmaceuticals. Find the stock by name or ticker symbol: AVIR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Atea Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Atea Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Atea Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Atea Pharmaceuticals share price

Use our graph to track the performance of AVIR stocks over time.

Atea Pharmaceuticals shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$24.15 - USD$90.95
50-day moving average USD$65.9877
200-day moving average USD$53.2664
Wall St. target priceUSD$82
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Atea Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atea Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Atea Pharmaceuticals under- or over-valued?

Valuing Atea Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Atea Pharmaceuticals's EBITDA

Atea Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$12 million.

The EBITDA is a measure of a Atea Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

To put Atea Pharmaceuticals's EBITDA into context you can compare it against that of similar companies.

Atea Pharmaceuticals financials

Revenue TTM USD$48.6 million
Operating margin TTM 24.7%
Gross profit TTM USD$33.7 million
Return on assets TTM 1.7%
Return on equity TTM -3.86%
Profit margin -22.51%
Book value N/A
Market capitalisation USD$4.5 billion

TTM: trailing 12 months

Shorting Atea Pharmaceuticals shares

There are currently 3.1 million Atea Pharmaceuticals shares held short by investors – that's known as Atea Pharmaceuticals's "short interest". This figure is 38.5% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Atea Pharmaceuticals shares can be evaluated.

Atea Pharmaceuticals's "short interest ratio" (SIR)

Atea Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Atea Pharmaceuticals shares currently shorted divided by the average quantity of Atea Pharmaceuticals shares traded daily (recently around 381409.57055215). Atea Pharmaceuticals's SIR currently stands at 8.15. In other words for every 100,000 Atea Pharmaceuticals shares traded daily on the market, roughly 8150 shares are currently held short.

To gain some more context, you can compare Atea Pharmaceuticals's short interest ratio against those of similar companies.

However Atea Pharmaceuticals's short interest can also be evaluated against the total number of Atea Pharmaceuticals shares, or, against the total number of tradable Atea Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atea Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Atea Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Atea Pharmaceuticals shares, roughly 41 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Atea Pharmaceuticals.

Find out more about how you can short Atea Pharmaceuticals stock.

Atea Pharmaceuticals share dividends

We're not expecting Atea Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Atea Pharmaceuticals overview

Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site